Parkinson's disease, Adaptive DBS and FDA-approved

FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.
FDA OKs First Adaptive DBS System for Parkinson’s Disease
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized neuromodulation that responds to the patient’s changing needs.
FDA-approved technology offers personalized treatment for Parkinson’s symptoms
Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.
Medtronic wins first FDA nod for adaptive DBS for Parkinson’s
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI).
FDA approves Medtronic’s brain stimulation system for Parkinson’s
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
FDA Approves Medtronic’s BrainSense Adaptive Deep Brain Stimulation for Parkinson Disease
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
Medtronic’s BrainSense brain stimulation system approved by FDA for Parkinson’s
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no
Medtronic plc: Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever
FDA approves Medtronic’s adaptive technology for Parkinson’s
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
Medtronic's deep brain stimulation system for Parkinson's disease wins FDA nod
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode Identifier.
Interesting Engineering on MSN6mon
Self-adjusting neuromodulation can enhance movement, sleep in Parkinson’s patients
‘Closed loop’ system to treat Parkinson’s disease Also called a “closed loop” system, the new treatment, aDBS strives to ...
Hosted on MSN1mon
Medtronic nets CE mark for Parkinson’s adaptive deep brain stimulation system
Medtronic has received CE marks under the European Union’s Medical Device Regulation (EU MDR) for the BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier (EI ...